ZINC ACETATE ANHYDROUS

US Approved OTC

First marketed in 1921

Details

Stereochemistry	ACHIRAL
Molecular Formula	2C2H3O2.Zn
Molecular Weight	183.497
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[Zn++].CC([O-])=O.CC([O-])=O

InChI

InChIKey=DJWUNCQRNNEAKC-UHFFFAOYSA-L

InChI=1S/2C2H4O2.Zn/c2*1-2(3)4;/h2*1H3,(H,3,4);/q;;+2/p-2

HIDE SMILES / InChI

Molecular Formula	C2H3O2
Molecular Weight	59.044
Charge	-1
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	Zn
Molecular Weight	65.409
Charge	2
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125327s020lbl.pdfhttp://www.chemistrylearner.com/zinc-hydroxide.html | http://www.lookchem.com/Zinc-hydroxide/https://www.google.com/patents/US3130034http://www.npi.gov.au/resource/zinc-and-compounds | https://www.ncbi.nlm.nih.gov/pubmed/27546855 | https://www.ncbi.nlm.nih.gov/pubmed/6353570http://www.azom.com/article.aspx?ArticleID=8415 | https://www.accessdata.fda.gov/scripts/fdcc/?set=IndirectAdditives&id=ZINCSULFIDE | http://www.imse.iastate.edu/files/2014/03/Jianqiang_Li_Master_Thesis.pdf | https://www.ncbi.nlm.nih.gov/pubmed/24477783https://www.ewg.org/skindeep/ingredient/724913/ZINC_CARBONATE/# | https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=582.80 | https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=347.10 | https://www.ncbi.nlm.nih.gov/pubmed/10378806 | https://www.ncbi.nlm.nih.gov/pubmed/17633459https://www.drugs.com/mtm/zinc-oxide-topical.htmlhttp://www.t3db.ca/toxins/T3D0733http://www.hmdb.ca/metabolites/HMDB01303
Curator's Comment: description was created based on several sources, including https://www.drugs.com/dosage/zinc-sulfate.html | https://www.ncbi.nlm.nih.gov/pubmed/10721938 | https://www.drugbank.ca/drugs/DB01593 | https://www.ncbi.nlm.nih.gov/pubmed/17132019

There is no available information related any biological and pharmaceutical application of ammonium tetrachlorozincate.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Streptococcus mutans 41 Target ID: CHEMBL612426 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12599434 \| https://www.ncbi.nlm.nih.gov/pubmed/2913640	Inhibitor 8504
respiratory burst 39 Target ID: GO:0045730 Sources: https://www.ncbi.nlm.nih.gov/pubmed/8157083	Activator 1447
transformed cell apoptotic process 104 Target ID: GO:0006927 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24477783	Activator 1447
Methotrexate 38 Target ID: CHEMBL2364710 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125327s020lbl.pdf	Hydrolytic Enzyme 38
ultraviolet B-induced damage 38 Target ID: ultraviolet B-induced damage Sources: https://www.ncbi.nlm.nih.gov/pubmed/25947194	Interacts 323
T cell mediated immunity 40 Target ID: GO:0002456 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24077486	Activator 1447
Zinc transporter ZIP1 38 Target ID: Q9NY26 Gene ID: 27173.0 Gene Symbol: SLC39A1 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/24077486	Binding Agent 1076
Zinc transporter ZIP2 38 Target ID: Q9NP94 Gene ID: 29986.0 Gene Symbol: SLC39A2 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/24077486	Binding Agent 1076

Conditions

Condition	Modality	Highest Phase	Product
Unknown 2596
Unknown 2596
Unknown 2596
Caries 43 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12599434 https://www.ncbi.nlm.nih.gov/pubmed/2913640 https://www.ncbi.nlm.nih.gov/pubmed/6353570	Preventing	Basic research	Unknown Approved Use Unknown
Ulcerative colitis 125 Sources: https://www.drugs.com/international/corticotropin-zinc-hydroxide.html https://www.ncbi.nlm.nih.gov/pubmed/13469787	Primary	Approved 8583	CORTROPHIN-ZINC Approved Use Treatment of ulcerative colitis and other colonic disorders. Launch Date 1955
Zinc deficiency 39 Sources: https://www.ncbi.nlm.nih.gov/pubmed/6383773	Primary	Preclinical	Unknown Approved Use Unknown
Acute myeloid leukemia 141 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24477783	Primary	Basic research	Unknown Approved Use Unknown
Breast cancer 432 Sources: https://www.ncbi.nlm.nih.gov/pubmed/27305766	Primary	Basic research	Unknown Approved Use Unknown
Renal insufficiency 40 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125327s020lbl.pdf	Secondary	Approved 8583	VORAXAZE Approved Use Indicated for the treatment of toxic plasma methotrexate concentrations (>1 micromole per liter) in patients with delayed methotrexate clearance due to impaired renal function. Limitation of use: VORAXAZE is not indicated for use in patients who exhibit the expected clearance of methotrexate (plasma methotrexate concentrations within 2 standard deviations of the mean methotrexate excretion curve specific for the dose of methotrexate administered) or those with normal or mildly impaired renal function because of the potential risk of subtherapeutic exposure to methotrexate. Launch Date 2012
Diaper dermatitis 38 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021026s000lbl.pdf	Primary	Approved 8583	VUSION Approved Use INDICATIONS AND USAGE VUSION Ointment is indicated for the adjunctive treatment of diaper dermatitis only when complicated by documented candidiasis (microscopic evidence of pseudohyphae and/or budding yeast), in immunocompetent pediatric patients 4 weeks and older. A positive fungal culture for Candida albicans is not adequate evidence of candidal infection since colonization with C. albicans can result in a positive culture. The presence of candidal infection should be established by microscopic evaluation prior to initiating treatment. VUSION Ointment should be used as part of a treatment regimen that includes measures directed at the underlying diaper dermatitis, including gentle cleansing of the diaper area and frequent diaper changes. Launch Date 2006
Poison Ivy dermatitis 38 Sources: https://www.drugs.com/cdi/zinc-oxide-cream.html	Primary	Approved 8583	ZINC OXIDE Approved Use Unknown
Gastrointestinal disorders 94 Sources: https://www.drugs.com/pro/zinc-sulfate-injection.html	Primary	Approved 8583	ZINC SULFATE Approved Use Unknown Launch Date 1987
Mucositis 39 Sources: https://clinicaltrials.gov/ct2/show/NCT01015183	Primary	Phase III 665	ZINC SULFATE Approved Use Unknown Launch Date 1987
Dysgeusia 38 Sources: https://clinicaltrials.gov/ct2/show/NCT00036881	Primary	Phase III 665	ZINC SULFATE Approved Use Unknown Launch Date 1987
Unknown 2596

PubMed

Title	Date	PubMed
In vitro activity of zinc salts against human rhinoviruses.	1987 Apr	3038000
A medicated polycarboxylate cement to prevent complications in composite resin therapy.	1990 Jan	2404104
New applications for the zinc iodide-osmium tetroxide technique.	1994 Feb	7512543
Iron chelators as therapeutic agents against Pneumocystis carinii.	1994 May	8067783
Cupric ion blocks NF kappa B activation through inhibiting the signal-induced phosphorylation of I kappa B alpha.	1995 Nov 13	7488149
Enantioselective Cyclopropanation of Allylic Alcohols. The Effect of Zinc Iodide.	1997 May 16	11671728
Thujaplicin-copper chelates inhibit replication of human influenza viruses.	1998 Aug	9806486
Combined effects of argon laser irradiation and fluoride treatments in prevention of caries-like lesion formation in enamel: an in vitro study.	1999 Spring	10686872
Structure of the 53BP1 BRCT region bound to p53 and its comparison to the Brca1 BRCT structure.	2002 Mar 1	11877378
Comparison of the levels of copper, zinc and iron in cervical mucus and in blood serum of women of childbearing age.	2004	16145958
Thermotoga maritima-Escherichia coli chimeric topoisomerases. Answers about involvement of the carboxyl-terminal domain in DNA topoisomerase I-mediated catalysis.	2004 Jul 16	15140883
Lysine beta311 of protein geranylgeranyltransferase type I partially replaces magnesium.	2004 Jul 16	15131129
Inhibition by copper(II) binding of hepatocyte growth factor (HGF) interaction with its receptor Met and blockade of HGF/Met function.	2004 Jul 30	15161915
High-throughput computational and experimental techniques in structural genomics.	2004 Oct	15489337
Impact of the mother's zinc deficiency on the woman's and newborn's health status.	2005	16240669
Erythrocyte zinc content in critically ill patients.	2005	16176172
[Zinc and aluminum concentrations in blood of hemodialysis patients and its impact on the frequency of infections].	2005	15901979
Zinc-induced anti-apoptotic effects in SH-SY5Y neuroblastoma cells via the extracellular signal-regulated kinase 1/2.	2005 Apr 27	15857667
Zinc in attention-deficit/hyperactivity disorder.	2005 Aug	16190793
Angiotensin II receptor blocker-induces blunted taste sensitivity: comparison of candesartan and valsartan.	2005 Aug	16042674
[Reduced thymulin production during occupational exposure to lead].	2005 Jan-Mar	15915658
Low dietary zinc decreases erythrocyte carbonic anhydrase activities and impairs cardiorespiratory function in men during exercise.	2005 May	15883427
Copper, zinc, and Cu/Zn ratio in carcinoma of the gallbladder.	2005 Sep 1	16118778
Effects of zinc supplementation in patients with type 1 diabetes.	2005 Summer	16034148
Zinc nutritional status of morbidly obese patients before and after Roux-en-Y gastric bypass: a preliminary report.	2006 Apr	16608609
Copper and zinc concentrations in serum of healthy Greek adults.	2006 Apr 15	15955548
Influence of dietary zinc and copper on digestive enzyme activity and intestinal morphology in weaned pigs.	2006 Dec	17093223
Marginal zinc deficiency increased the susceptibility to acute lipopolysaccharide-induced liver injury in rats.	2006 May	16636303
On the mechanism of the conversion of methanol to 2,2,3-trimethylbutane (triptane) over zinc iodide.	2006 Nov 10	17081022
Assessing toxicity of fine and nanoparticles: comparing in vitro measurements to in vivo pulmonary toxicity profiles.	2007 May	17301066
DNA damaging potential of zinc oxide nanoparticles in human epidermal cells.	2009 Mar 28	19382294
Metal oxide nanoparticles induce unique inflammatory footprints in the lung: important implications for nanoparticle testing.	2010 Dec	20729176
In vivo uptake and acute immune response to orally administered chitosan and PEG coated PLGA nanoparticles.	2010 Dec 1	20851137
Oxidative stress, calcium homeostasis, and altered gene expression in human lung epithelial cells exposed to ZnO nanoparticles.	2010 Feb	19755143
Engineered nanomaterials cause cytotoxicity and activation on mouse antigen presenting cells.	2010 Jan 12	19897006
Phosphorylation of p65 is required for zinc oxide nanoparticle-induced interleukin 8 expression in human bronchial epithelial cells.	2010 Jul	20194077
Zinc oxide nanoparticle disruption of store-operated calcium entry in a muscarinic receptor signaling pathway.	2010 Oct	20708676
Quantum dots trigger immunomodulation of the NFκB pathway in human skin cells.	2011 Jul	21481475
Glucarpidase rescue in a patient with high-dose methotrexate-induced nephrotoxicity.	2011 Jun	19833686
High-dose methotrexate-induced renal dysfunction: is glucarpidase necessary for rescue?	2011 Mar 1	21220601
Responses of human cells to ZnO nanoparticles: a gene transcription study.	2011 Nov	21769377
Distinct immunomodulatory effects of a panel of nanomaterials in human dermal fibroblasts.	2012 May 5	22342292
Zinc oxide nanoparticles inhibit Ca2+-ATPase expression in human lens epithelial cells under UVB irradiation.	2013 Dec	24060544
Mechanism of uptake of ZnO nanoparticles and inflammatory responses in macrophages require PI3K mediated MAPKs signaling.	2014 Apr	24368203
Nanosized zinc oxide particles do not promote DHPN-induced lung carcinogenesis but cause reversible epithelial hyperplasia of terminal bronchioles.	2014 Jan	23832296
Zinc oxide nanoparticles induce migration and adhesion of monocytes to endothelial cells and accelerate foam cell formation.	2014 Jul 1	24746987
Additive effect of zinc oxide nanoparticles and isoorientin on apoptosis in human hepatoma cell line.	2014 Mar 3	24374571
Immunomodulatory activity of zinc peroxide (ZnO₂) and titanium dioxide (TiO₂) nanoparticles and their effects on DNA and protein integrity.	2014 May 16	24631018
Zinc oxide nanoparticles induce apoptosis by enhancement of autophagy via PI3K/Akt/mTOR inhibition.	2014 May 16	24614525
Synthesis aspects, structural, spectroscopic, antimicrobial and room temperature ferromagnetism of zinc iodide complex with Schiff based ligand.	2015 Jan 25	25173522

Patents

Sample Use Guides

In Vivo Use Guide

single intravenous injection of 50 Units per kg

Route of Administration: Intravenous

In Vitro Use Guide

Unknown

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:46:38 GMT 2025` Edited by `admin` on `Mon Mar 31 18:46:38 GMT 2025`
Record UNII	H2ZEY72PME
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

ZINCUM ACETICUM

Preferred Name

English

ZINC ACETATE ANHYDROUS

Common Name

English

NSC-75801

Code

English

ZINCUM ACETICUM [HPUS]

Common Name

English

ZINC(II) ACETATE

Systematic Name

English

NANO-DTPA CAPSULE COMPONENT ZINC ACETATE

Brand Name

English

ANHYDROUS ZINC ACETATE

Common Name

English

Zinc acetate [WHO-DD]

Common Name

English

ZINC ACETATE [MI]

Common Name

English

ANHYDROUS ZINC ACETATE [MART.]

Common Name

English

NANODTPA COMPONENT ZINC ACETATE

Brand Name

English

ACETIC ACID, ZINC(II) SALT

Common Name

English

ZINC ACETATE ANHYDROUS [HSDB]

Common Name

English

NANODTPA ZN-DTPA COMPONENT ZINC ACETATE

Brand Name

English

Code System Code Type Description

CHEBI

62984